AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16, 2017
August 08 2017 - 7:00AM
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare diseases, today announced that Sue Washer, President and
Chief Executive Officer, will present at the Wedbush PacGrow
Healthcare Conference on Wednesday, August 16, 2017 at 9:45am ET in
New York.
AGTC's lead product candidates are designed to
treat inherited orphan diseases of the eye, caused by mutations in
single genes that significantly affect visual function and
currently lack effective medical treatments.
AGTC's pipeline includes ophthalmology programs
in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa
(XLRP), achromatopsia caused by mutations in the CNGB3 and CNGA3
genes, wet age-related macular degeneration and an optogenetics
program with Bionic Sight.
A live audio webcast of the presentation will be
accessible by visiting ir.agtc.com/events.cfm. A replay will be
available on the company’s website following the event.
About AGTC
AGTC is a clinical-stage biotechnology company
that uses its proprietary gene therapy platform to develop products
designed to transform the lives of patients with severe diseases,
with an initial focus in ophthalmology. AGTC's product pipeline
includes ophthalmology programs in X-linked retinoschisis (XLRS),
X-linked retinitis pigmentosa (XLRP), achromatopsia, wet
age-related macular degeneration, and an optogenetics program with
Bionic Sight. AGTC's non-ophthalmology programs include its
adrenoleukodystrophy program and its otology program, which is in
pre-clinical development, and the company expects to advance
several otology product candidates into clinical development in the
next few years. Each of AGTC's XLRS, XLRP and adrenoleukodystrophy
programs are part of its collaboration and license agreement with
Biogen. AGTC employs a highly-targeted approach to selecting and
designing its product candidates, choosing to develop therapies for
indications having high unmet medical need that it believes are
clinically feasible and present commercial opportunities. AGTC has
a significant intellectual property portfolio and extensive
expertise in the design of gene therapy products including capsids,
promoters and expression cassettes, as well as, expertise in the
formulation, manufacture and physical delivery of gene therapy
products.
IR/PR CONTACTS:
David Carey (IR)
Lazar Partners Ltd.
T: (212) 867-1768
dcarey@lazarpartners.com
Corporate Contacts:
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024